Perceptive Advisors’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-6,825,395
| Closed | -$146M | – | 131 |
|
|
2024
Q1 | $146M | Buy |
6,825,395
+4,074,000
| +148% | +$48.7M | 2.55% | 7 |
|
|
2023
Q4 | $26.4M | Hold |
2,751,395
| – | – | 0.59% | 45 |
|
|
2023
Q3 | $7.15M | Hold |
2,751,395
| – | – | 0.24% | 66 |
|
|
2023
Q2 | $12.8M | Sell |
2,751,395
-8,541
| -0.3% | -$36.9K | 0.37% | 62 |
|
|
2023
Q1 | $10.4M | Buy |
+2,759,936
| New | +$10.9M | 0.31% | 64 |
|
|
2022
Q3 | – | Sell |
-1,052,445
| Closed | -$2.62M | – | 126 |
|
|
2022
Q2 | $2.62M | Sell |
1,052,445
-174,572
| -14% | -$802K | 0.08% | 93 |
|
|
2022
Q1 | $9.5M | Hold |
1,227,017
| – | – | 0.2% | 83 |
|
|
2021
Q4 | $5.12M | Sell |
1,227,017
-27,590
| -2% | -$172K | 0.08% | 119 |
|
|
2021
Q3 | $9.9M | Sell |
1,254,607
-520,560
| -29% | -$4.38M | 0.14% | 103 |
|
|
2021
Q2 | $14.3M | Sell |
1,775,167
-175,000
| -9% | -$1.51M | 0.19% | 101 |
|
|
2021
Q1 | $20.9M | Sell |
1,950,167
-285,816
| -13% | -$3.34M | 0.26% | 75 |
|
|
2020
Q4 | $26.3M | Hold |
2,235,983
| – | – | 0.28% | 74 |
|
|
2020
Q3 | $26.9M | Hold |
2,235,983
| – | – | 0.39% | 58 |
|
|
2020
Q2 | $36M | Buy |
+2,235,983
| New | +$38.9M | 0.58% | 43 |
|
Perceptive Advisors's FUSN Position: Q2 2024 in Review
Perceptive Advisors sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q2 2024, closing a stake of 6,825,395 shares — an estimated $146M sold.
Perceptive Advisors first reported a position in FUSN in Q2 2020 and held it in 14 quarters. The position peaked at $146M in Q1 2024. 0 funds tracked by Wall St. Rank hold FUSN as of Q2 2024.
- Perceptive Advisors reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q2 2024 after selling out during the quarter.
- Perceptive Advisors sold 6,825,395 Fusion Pharmaceuticals Inc. Common Shares shares in Q2 2024, an estimated $146M.
- Perceptive Advisors first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q2 2020 and held it in 14 quarters.
- Perceptive Advisors's Fusion Pharmaceuticals Inc. Common Shares position peaked at $146M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q2 2024.
Based on Perceptive Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.